C. Wang

Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)

C. Zhou, Yi‐Long Wu, G. Chen et al. · Annals of Oncology · 2015 · 464 citations

Non-small-cell Lung Cancer, Medicine, Pathology +8

Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)

G. Chen, J. Feng, Caicun Zhou et al. · Annals of Oncology · 2013 · 119 citations · Full text

Medicine, Cancer Management, Phase Iii +6

LBA58 Pathological response to neoadjuvant tislelizumab (TIS) plus platinum-doublet (PtDb) chemotherapy (CT) in resectable stage II-IIIA NSCLC patients (pts) in the phase III (Ph3) RATIONALE-315 trial

Dongsheng Yue, Wenxin Wang, Huai Liu et al. · Annals of Oncology · 2023 · 36 citations · Full text

Surgical Oncology, Lba58 Pathological Response, Medicine +10

VP1-2024: RATIONALE-315: Event-free survival (EFS) and overall survival (OS) of neoadjuvant tislelizumab (TIS) plus chemotherapy (CT) with adjuvant TIS in resectable non-small cell lung cancer (NSCLC)

Dongsheng Yue, Wenxiang Wang, Haibo Liu et al. · Annals of Oncology · 2024 · 35 citations · Full text

Nursing management at a Chinese fever clinic during the COVID‐19 pandemic

Y. Wang, Wanmin Qiang, C. Wang et al. · International Nursing Review · 2021 · 24 citations · Full text